A Phase I/II Trial of ZIO-101 in Advanced Multiple Myeloma
Phase 1/Phase 2
18 Years
N/A
18 Years
N/A
Not Enrolling
Both
Multiple Myeloma
Both
Multiple Myeloma
Trial Information
A Phase I/II Trial of ZIO-101 in Advanced Multiple Myeloma
Inclusion Criteria
Subjects with multiple myeloma who have received at least two prior therapies and
currently require therapy.
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Phase I: toxicity defined in the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events v3.0 (CTCAE) 12/12/03
Outcome Time Frame:
6 months
Safety Issue:
Yes
Authority:
United States: Food and Drug Administration
Study ID:
SGL2001
NCT ID:
NCT00303199
Start Date:
January 2006
Completion Date:
August 2007
Related Keywords:
- Multiple Myeloma
- Multiple Myeloma
- Arsenic
- Cancer study
- Failed treatment
- Multiple Myeloma
- Neoplasms, Plasma Cell
Name | Location |
|---|---|
| Fountain Valley, California 92708 | |
| Miami, Florida 33176 | |
| Albany, New York 12208 | |
| Cleveland, Ohio 44195 | |
| Little Rock, Arkansas 72205-7199 | |
| Baltimore, Maryland 21287 |
